<!doctype html>
<html lang="en">
    <head>
        <meta charset="utf-8">
        <title>Michael L. Bernauer</title>
        <meta name="description" content="A framework for easily creating beautiful presentations using HTML">
        <meta name="author" content="Michael L. Bernauer">
        <meta name="apple-mobile-web-app-capable" content="yes">
        <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">
        <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no, minimal-ui">
        <link rel="stylesheet" href="../reveal/css/reveal.css">
        <link rel="stylesheet" href="../reveal/css/theme/serif.css" id="theme">
        <!-- Code syntax highlighting -->
        <link rel="stylesheet" href="../reveal/lib/css/zenburn.css">
        <!-- Printing and PDF exports -->
        <script>
            var link = document.createElement( 'link' );
            link.rel = 'stylesheet';
            link.type = 'text/css';
            link.href = window.location.search.match( /print-pdf/gi ) ? '../reveal/css/print/pdf.css' : '../reveal/css/print/paper.css';
            document.getElementsByTagName( 'head' )[0].appendChild( link );
        </script>
        <!--[if lt IE 9]>
        <script src="lib/js/html5shiv.js"></script>
        <![endif]-->
    </head>
    <body>

        <div class="reveal">

            <!-- Any section element inside of this container is displayed as a slide -->
            <div class="slides">
<section>
<section data-markdown>
<script type="text/template">
## Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study

<div class="center">Created by [Michael L. Bernauer](http://mlbernauer.com)</div>

<div calss="center">APPE-8: UNMH Internal Medicine - Allison Burnett, PharmD</center>

<div class="center">_January 16, 2016_</div>
</script>
</section>
<section data-markdown>
<script type="text/template">
# Meta
### Funding
* Boehringer-Ingelheim

### Acceptance date
* October 12, 2015

### Publication date
* November 16, 2015

### Study design:
* Retrospective cohort

### Study site:
* University of Birmingham Centre for Cardiovascular Sciences, Birmingham City Hospital, Birmingham UK
</script>
</section>
</section>
<section data-markdown>
<script type="text/template">
# Background
* Atrial fibrillation is the leading cause of stroke
* Anticoagulation reduces risk of afib associated stroke
* Anticoagulation increases risk for developing bleed
* GI tract is the most common site of bleeding due to oral anticoag treatment in patients with afib
* Up to 50.9% of patients with atrial fibrillation do not resume therapy after GI bleed<small>2</small>
* Little data exist on whether to restart antithrombotic treatment or withold treatment after GI bleed 

_<small>1. Needs citation <br>2. Quereshi W, Mittal C, Patsias I, et al. Am J Cardiol 2014;113:662-8.</small>_
</script>
</section>
<section data-markdown>
<script type="text/template">
# Objective
<div class="center"><large>_"Examine the risk of all cause mortality and hospital admission or death due to thromoembolism, major bleeding, or recurrent GI bleeding associated with restarting antithrombotic treatment after a GI bleed in patients with atrial fibrillation."_</large></div>
</script>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Methods
</script>
</section>
<section data-markdown>
<script type="text/template">
## Patient registries
* **Danish National Patient Registry**: information on hospital admission data.
    * Primary and secondary diagnoses
    * Procedures and surgical opearations
* **Danish National Prescription Registry**: records all claimed drug prescriptions form pharmacies in Denmark
* **Danish Civil Registration System**: contains information about an individual's vital status and cause of death
</script>
</section>
<section data-markdown>
<script type="text/template">
## Study population
### Inclusion
* Atrial fibrillation
* Experienced GI bleeding while receiving vitamin K antagonist, dabigatran, rivaroxaban, aspirin, clopidogrel, prasugrel, ticagrelor.
* Patients enrolled on first day of discharge following first time admission for GI bleed during period of 1/1/96 to 12/31/12

### Exclusion
* 30 &gt; Age &gt; 100
* Valvular heart disease
* Total hip or knee replacement surgery &le; 8 weeks before inclusion event
* DVT or PE &le; 6 months before inclusion event
* Death or thromboembolic event, major bleeding, recurrent GI bleed within 90 days after inclusion event
</script>
</section>
<section data-markdown>
<script type="text/template">
## Antithrombotic treatment

### Single oral anticoagulant (OAC)
* Vitamin K antagonist, dabigatran, rivaroxaban

### Single antiplatelet
* Aspirin, clopidogrel, prasugrel, ticagrelor

### Dual or triple therapy<small>*</small>
* Oral anticoagulation, aspirin, clopidogrel, prasugrel, ticagrelor

_<small><sup>*</sup></small><small>The number of patients restarting on triple therapy was small and therefore excluded from analysis.</small>_
</script>
</section>
<section data-markdown>
<script type="text/template">
## Concomitant medical treatment and comorbidities
### Concomitant meds
* Concomitant medications used during bleeding event were identified using prescription fill history during the 90 days leading up to the inclusion event.
* Concomitant medicaitons used at baseline were determined using prescription fill history during the 90 day blanking peroid

### Comorbidities
* Stroke risk was assessed using CHADS<sub>2</sub> and CHA<sub>2</sub>DS<sub>2</sub>-VASc scores
    * CHF, HTN, Age &ge; 75, DM, Stroke or TIA (Vascular disease, Age 65 to 74, Sex[F])
* Bleeding risk was assessed using HAS-BLED scores
    * HTN, abnormal renal/liver function, stroke, previous bleed, INR, age &ge; 65, drugs (antiplatelet agents, NSAIDs) or EtOH abuse.
</script>
</section>
<section data-markdown>
<script type="text/template">
## Outcomes and follow-up
### Outcomes
* All cause mortality
* Admission to hospital
* Death due to thromboembolism
    * Defined as ischemic stroke, transient ischemic attack, systemic thromboembolism
* Major bleeding
    * Intracranial bleeding, severe bleeding from respiratory system, GI or urinary tract
* Recurrent GI bleeding
    * Defined using all diagnosis codes for GI bleeding

### Follow-up
* Follow up occurred until either of the outcomes: death, five year follow-up, or Dec 31, 2012, whichever came first.
</script>
</section>
<section data-markdown>
<script type="text/template">
## Statistical analysis
* Baseline characteristics were represented using means and standard deviations
* Independence/homogeneity was assessed using &chi;<small>2</small> tests
* Cumulative incidence of outcomes was assessed using the Aalen-Johansen method
* Time dependent Cox proportional hazards models were used to examine the risk of events during follow-up
* Significance was determined using two-sided &alpha; of &lt; 0.05
</script>
</section>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Results
</script>
</section>
<section data-markdown>
<script type="text/template">
## Enrollment
</script>
</section>
<section data-background="flow.svg" data-background-size="95%">
</section>
<section data-markdown>
## Demographics
</section>
<section data-background="demo.svg" data-background-size="80%">
</section>
<section data-markdown>
<script type="text/template">
## Baseline characteristics
</script>
</section>
<section data-background="baseline.svg" data-background-size="40%">
</section>
<section data-markdown>
<script type="text/template">
## Cumulative incidence
</script>
</section>
<section data-background="cumplot.svg" data-background-size="75%">
</section>
<section data-markdown>
<script type="text/template">
## Risk associated with anticoagulation

| Outcomes            | No of events | Single OAC                    | Single antiplatelet     | Anticoagulant + Antiplatelet | Aspirin + P2Y<sub>12</sub> inhibitor                |
|---------------------|--------------|-------------------------------|-------------------------|------------------------------|-----------------------------------------------------|
| All cause mortality | 1730         | **0.39** (0.34 to 0.46)       | **0.76** (0.68 to 0.86) | **0.41** (0.32 to 0.52)      | 0.88 (0.57 to 1.36)                                 |
| Thromboembolism     | 496          | **0.41** (0.31 to 0.54)       | **0.76** (0.61 to 0.95) | **0.54** (0.36 to 0.82)      | 0.79 (0.34 to 1.84)                                 |
| Major bleeding      | 454          | **1.37** (1.06 to 1.77)       | 1.25 (0.96 to 1.62)     | 1.44 (1.00 to 2.08)          | 1.36 (0.54 to 3.43)                                 |
| Recurrent GI bleed  | 216          | 1.22 (0.84 to 1.77)           | 1.19 (0.82 to 1.74)     | 1.34 (0.79 to 2.28)          | 0.58 (0.08 to 4.30)                                 |

<small>**Table 1.** Main results presenting hazard ratios (95% confidence intervals) for restarting antithrombotic treatment and associated risk of outcome.</small>
</script>
</section>
<section data-markdown>
<script type="text/template">
## Subgroup analysis
* **Higher CHA<sub><small>2</small></sub>DS<sub><small>2</small></sub>-VASc** score at inclusion event was associated with **decreased risk** of **all cause mortality** in patients receiving single OAC
* **HAS-BLED score &gt; 3** at inclusion event showed **increased risk of recurrent GI bleed** in patients receiving SOA
</script>
</section>
<section data-markdown>
<script type="text/template">
## Concomitant PPI use after GI bleeding

| Outcomes            |  Single OAC                    | Single antiplatelet     | Anticoagulant + Antiplatelet | Aspirin + P2Y<sub>12</sub> inhibitor |
|---------------------|--------------------------------|-------------------------|------------------------------|-----------------------------------------------------|
| All cause mortality |  **0.38** (0.32 to 0.45)       | **0.75** (0.67 to 0.85) | **0.41** (0.31 to 0.53)      | 0.78 (0.49 to 1.24)                                 |
| Thromboembolism     |  **0.40** (0.30 to 0.54)       | **0.75** (0.60 to 0.95) | **0.57** (0.37 to 0.87)      | 0.77 (0.33 to 1.80)                                 |
| Major bleeding      |  **1.45** (1.10 to 1.91)       | 1.26 (0.95 to 1.67)     | **1.50** (1.02 to 2.22)      | 1.44 (0.57 to 3.68)                                 |
| Recurrent GI bleed  |  1.26 (0.85 to 1.87)           | 1.09 (0.73 to 1.64)     | 1.30 (0.74 to 2.29)          | 0.58 (0.08 to 4.36)                                 |

<small>**Table 2.** Subgroup analysis including patients with additional proton pump inhibitor use with hazard ratios (95% confidence intervals) for restart of antithrombotic treatment and associated risk of outcome</small>
</script>
</section>
</section>
<section>
<section data-markdown>
<script type="text/template">
# Discussion
* Cumulative incidence of death was high (39.9%) within 2 years of inclusion event
* 27.1% of patients did not resume antithrombotic treatment after experiencing GI bleed
* Restarting treatment with single OAC was associated with lowest risk of all cause mortality and thromboembolism (HR 0.39 [0.34-0.46], 0.41 [0.31-0.54]) compared with non-resumption of therapy
* None of the treatments were associated with increased risk of recurrent GI bleed
</script>
</section>
<section data-markdown>
<script type="text/template">
## Strengths and limitations
### Strengths
* Nation wide cohort, 4,602 patients with atrial fibrillation
* Low bias: data observed independent of sex, age, socioeconomic status or participation in health insurance programs
* Danish national prescription registry allows assessment of concomitant medications
* Sensitivity and subgroup analyses support authors conclusions

### Limitations
* Study design does not allow determination of causation
* No way to directly assess adherence
* Patients with inclusion events close to Dec 31, 2012 may not have had sufficient follow-up time to manifest outcomes
* Results regarding recurrent GI bleed may be optimistic due to limited follow-up period (5 years)
* No way to distinguish between upper or lower GI bleed
* Limitation of registries revent the study of INR, warfarin adherence, serum creatinine, renal function, hemaglobin and other potential confounders

</script>
</section>
</section>
<section data-markdown>
<script type="text/template">
# Conclusion
* Results support resumption of antithrombotic treatment after experiencing GI bleed
* Single OAC was associated with the largest reduction in all cause mortality/thromboembolism however also associated with an increase in major bleeding 
* Single antiplatelet thearpy associated with reduction in all cause mortality and trhomboembolism without increasing risk of major bleed
* None of the treatments were associated with an increased risk of recurrent GI bleed compared to non-resumption of therapy 
</script>
</section>
<section data-markdown>
<script type="text/template">
# Author affiliations
* **Gregory Y H Lip**: Bayer, Astellas, Merck, Sanofi, Pfizer/Bristol-Myers Squibb, Daiichi-Sankyo, Biotronik, Medtronic, Portola, **Boehringer Ingelheim**
* **Jonas B Olesen**: Bristol Myers Squibb, **Boehringer Ingelheim**, Lundbeck Foundation, Bristol-Myers Squibb, Capital Region of Denmark, Foundation for Health Research
* **Emil L Fosb&oslash;l**: Janssen Pharmaceuticals, Lundbeck Foundation, Bristol-Meyers Squibb
* **Anna Gundlund**: Bristol-Myeres
* **Gunnar H Gislason**: Pfizer/Bristol-Myers Squibb, Bayer, **Boehringer-Ingelheim**, AstraZeneca

_All authors state independence from the funders_
</script>
</section>
<section data-markdown>
<script type="text/template">
# Citation
1. Staerk L, Lip GY, Olesen JB, Fosb√∏l EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ. 2015 Nov 16;351:h5876. doi: 10.1136/bmj.h5876. PubMed PMID: 26572685; PubMed Central PMCID: PMC4646074
</script>
</section>

        </div>
        <script src="../reveal/lib/js/head.min.js"></script>
        <script src="../reveal/js/reveal.js"></script>
        <script>
            // Full list of configuration options available at:
            // https://github.com/hakimel/reveal.js#configuration
            Reveal.initialize({
                controls: true,
                progress: true,
                history: true,
                center: true,
                transition: 'convex', // none/fade/slide/convex/concave/zoom
                // Optional reveal.js plugins
                dependencies: [
                    { src: '../reveal/lib/js/classList.js', condition: function() { return !document.body.classList; } },
                    { src: '../reveal/plugin/markdown/marked.js', condition: function() { return !!document.querySelector( '[data-markdown]' ); } },
                    { src: '../reveal/plugin/markdown/markdown.js', condition: function() { return !!document.querySelector( '[data-markdown]' ); } },
                    { src: '../reveal/plugin/highlight/highlight.js', async: true, condition: function() { return !!document.querySelector( 'pre code' ); }, callback: function() { hljs.initHighlightingOnLoad(); } },
                    { src: '../reveal/plugin/zoom-js/zoom.js', async: true },
                    { src: '../reveal/plugin/notes/notes.js', async: true }
                ]
            });
            Reveal.configure({backgroundTransition: 'zoom'});
        </script>
    </body>
</html>
